Announcements
- BiVictriX – Full Year Results 2023
- Orphan Drug Designation & FDA INTERACT Meeting
- Grant of Options – PDMR/Director Dealings
- Holding(s) in Company
- BiVictriX Hosts Inaugural Roundtable Discussion
- Board Change
- Pipeline update on BVX002
- Patent Granted in Japan
- Extended Survival Rates Reported with BVX001
- Appointment of Adrian Howd as CFO and CBO
More ▼
Key statistics
On Friday, BiVictriX Therapeutics PLC (4DE:FRA) closed at 0.1270, 24.51% above the 52 week low of 0.102 set on Jan 03, 2024.
52-week range
Open | 0.123 |
---|---|
High | 0.1270 |
Low | 0.116 |
Bid | 0.123 |
Offer | 0.138 |
Previous close | 0.116 |
Average volume | 0.00 |
---|---|
Shares outstanding | 82.53m |
Free float | 51.08m |
P/E (TTM) | -- |
Market cap | 9.49m GBP |
EPS (TTM) | -0.0352 GBP |
Data delayed at least 15 minutes, as of May 31 2024 14:29 BST.
More ▼